02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
23:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb  Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:50 , Jun 11, 2019 |  BC Extra  |  Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

Genmab, Janssen partner on next-gen CD38 mAb Genmab A/S (CSE:GEN; Pink:GMXAY) granted Janssen Biotech Inc. an option to HexaBody-CD38, building on the companies' collaboration on multiple myeloma CD38 mAb Darzalex daratumumab. Genmab will fund R&D...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
23:24 , May 15, 2019 |  BC Extra  |  Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
18:06 , Apr 10, 2019 |  BC Extra  |  Company News

ICER draft report: Aimmune's peanut allergy therapy cost effective, DBV's falls short

ICER thinks Aimmune's peanut allergy therapy AR101 could be cost effective but found that DBV’s Viaskin Peanut exceeded standard cost-effectiveness ratios, according to a draft evidence report published Tuesday. The institute said both therapies may...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
19:34 , Apr 4, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Sangamo, Tricida, DBV

Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts. DBV also raised a follow-on ahead of a planned BLA resubmission. Sangamo Therapeutics Inc. (NASDAQ:SGMO) raised $126.5 million on...